论文部分内容阅读
不久前在美国心脏学会的会议上,研究者们介绍,早期干预急性心肌梗塞(AMI),使病死率降低,梗塞范围缩小。但专题讨论主持人,哈佛大学内科教授E Braunwald则认为由于AMI治疗水平整个地提高了,评价这些治疗的效果还有困难。法国Rolf-Shroder介绍了欧洲的静脉链激霉滴注治疗急性心肌梗塞(ISAM)的第一篇报告,反映接受这种治疗的病人,梗塞范围有一定程度的缩小,症状发生3小时内开始治疗者疗效最好。但Braunwald指出,ISAM的安慰剂组病后21日病死率仅7％,意外
Not long ago at a meeting of the American Heart Association, researchers described that early intervention with acute myocardial infarction (AMI) reduced mortality and reduced infarct size. However, Moderator Ebraunwald, a professor of medicine at Harvard University, said that as the overall level of treatment for AMI has risen, there is still some difficulty in assessing the efficacy of these treatments. Rolf-Shroder from France introduced the first report of intravenous streptomycin instillation in Europe for the treatment of acute myocardial infarction (ISAM), reflecting that patients receiving this treatment had a somewhat reduced infarct size and started treatment within 3 hours of symptom onset The best effect. But Braunwald pointed out that the ISAM placebo group died of a 21% fatality rate of only 7% after the accident